CTI Tumbles 47 Percent On Missed Endpoint For Xyotax March 8, 2005 Cell Therapeutics Inc. lost almost half of its value Monday, following news that Xyotax missed the primary endpoint in its Stellar 3 pivotal trial in non-small-cell lung cancer patients. (BioWorld Today)Read More
RSS